Study of IBI323 in Patients With Advanced Malignancies
Status:
Recruiting
Trial end date:
2023-03-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety, tolerability and efficacy of
IBI323(anti-LAG-3/PD-L1) or in combination with chemotherapy in participants with advanced
malignancies. Another purpose is to determine the pharmacokinetics,pharmacodynamics and
immunogenicity of IBI323